Home
/
Cullinan Therapeutics, Inc.
/
Financials
/
Quarterly
Cullinan Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Cullinan Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2022
Sep 30, 2022
$0
Nov 14, 2022
Q2
2022
Jun 30, 2022
$0
Aug 10, 2022
Q1
2022
Mar 31, 2022
$0
May 16, 2022
Q3
2022
Sep 30, 2021
$0
Nov 14, 2022
Q2
2022
Jun 30, 2021
$0
Aug 10, 2022
Q1
2022
Mar 31, 2021
$18.94M
May 16, 2022
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($50.61M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($70.06M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($48.50M)
May 8, 2025
Q3
2025
Sep 30, 2024
($40.56M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($42.03M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($37.15M)
May 8, 2025
Q3
2024
Sep 30, 2023
($39.18M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($32.21M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($57.96M)
May 15, 2024
Q3
2023
Sep 30, 2022
($24.80M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
$174.90M
Aug 10, 2023
Q1
2023
Mar 31, 2022
($12.10M)
May 11, 2023
Q3
2022
Sep 30, 2021
($17.35M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($15.64M)
Aug 10, 2022
Q1
2022
Mar 31, 2021
($70.0K)
May 16, 2022
Q3
2021
Sep 30, 2020
($9.86M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($8.62M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($4.97M)
May 14, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($55.60M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($75.80M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($55.00M)
May 8, 2025
Q3
2025
Sep 30, 2024
($48.86M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($50.03M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($42.99M)
May 8, 2025
Q3
2024
Sep 30, 2023
($45.24M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($37.61M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($62.76M)
May 15, 2024
Q3
2023
Sep 30, 2022
($29.77M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
$239.68M
Aug 10, 2023
Q1
2023
Mar 31, 2022
($32.66M)
May 11, 2023
Q3
2022
Sep 30, 2021
($18.38M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($16.60M)
Aug 10, 2022
Q1
2022
Mar 31, 2021
$1.37M
May 16, 2022
Q3
2021
Sep 30, 2020
($11.50M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($14.12M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($5.54M)
May 14, 2021